Home  /  Resource Library  /  TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): RESULTS FROM THE PHASE 3 INMIND STUDY

TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): RESULTS FROM THE PHASE 3 INMIND STUDY

EHA 2025